🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

In HER2 mutant and HER2 overexpression aNSCLC the combination of TRASTUZUMAB DERUX ➕ Pembro is promising and synergistic but safety 🆘could raise some concerns specially in HER2m. A strategy to follow as could replace CT strategies in 1st line in this population #ESMOImmuno24

2024: Fortunately is difficult to merge all ttx for NSCLC 🫁 in 1 slide. Hwv, still pending: ✏️avoid “me too” approvals if prices not ⬇️ ✏️ consol TKI for all and for lifetime? ✏️⬆️genotyping access & drug access ✏️➕ academic trials of de-escalating ✏️periop vs neoadj@OncoAlert

Inspired by my good friend and slide master Jordi Remon - sharing these updated summary slides for 1L and post-progression treatment options for advanced stage EGFR-mutated NSCLC. Might be outdated soon but hopefully not before 2025 😬 OncoAlert

🎺TelisoV+Osi potential ttx in MET overex meta EGFRm NSCLC with osi resist disease 👏🏻. Hw: ✏️Other ADCs with activity ✏️Not easy tissue Bx at PD for testing MET ✏️New 1stL options may ⬇️ MET expression at PD? ✏️🧠 activity Stephanie Saw Hidehito HORINOUCHI doi.org/10.1016/j.anno…

IO has changed ttx and outcome in adv 🫁.It’s time that Academic trials (PULSE Benjamin Besse )and international grants test IO de-escalation to ensure ➕ pts receive these drugs, ⬆️outcomes to more pts worldwide, while ⬇️financial tox.Thk all authors!👏🏻 ascopubs.org/doi/10.1200/JC…

Personalised approach at osimertinib PD with savolitinib and osimertinib in MET deregulated EGFRm NSCLC looks promising. Is it better than CT+Ami or ADC? Hwr, it is a chemofree strategy and other treatments could be applied later #ELCC25

BAY2927088 a TKI antiHER2 ⬆️activity in HER2naive and HER2-pretxt pts with HER2m.3 ongoing ph3 in 1st L (T-Dxd, BAY2927088, zongertinib) vs CT-IO What will be winner 🤷🏻‍♂️?Important to look across trials: mPFS,🧠activity,side-effects.Role for T-Dxd+TKI antiHER2? Sequential? #ELCC25

We had efficacy data ADCs after osi-PD in EGFRm NSCLC. Today good mPFS (9.5-11.7) with Osi+DatopotamAb Dxd after osi-PD. Data looks ➕promising than chemo+Amiv. Better 🧠 protection maintaining osi? Biomarker for dato? Toxicity is imp. Future trial: osi-DATOD vs Ami-CT? #ELCC25

Adagrasib 400 mg + Pembrolizumab impressive mPFS in KRAS G12C mutant NSCLC and PDL1 >50% and good safety. Better than IO or CT+IO alone. Good chemo free strategy for patients Await for ph3 trial. #ELCC2025

After atezolizumab subcutaneous we have Pembrolizumab sc that is not inferior to pembrolizumab iv in 1st line in aNSCLC. Hwr, do we need this sc formulation every 6 weeks? New option on daily practice but what about price? #ELCC2025

Cooperative Academic groups like #EORTC Lung Cancer Group are amazing!We have made our Spring meeting in Genova 🇮🇹with an outstanding group of Young Investigators 👏🏻.Lots ideas for future academic trials to ⬆️outcome of pts with 🫁 cancers. Working Together makes us stronger💪🏻

DB-1310 is a new ADC anti-HER3 with pantumor activity including NSCLC with promising activity in EGFRm 🫁. Based on disappointing results with HERTHENALung trial, next step should be DB-1310 + osimertinib in osimertinib-PD disease? #ASCO25

BL-B01D1 bispecific ADC anti EGFR xHER3. Ph1 trial in 🫁 with genomic alt other than common EGFRm. ORR 46%. PFS 7 mo. Despite limited sample in each cohort, data suggest activity of this ADC in NSCLC with AGAs. Pending to improve tox profile (80% G3 TRAEs). icORR? #ASCO25

Pembro +adagrasib in KRAS G12C NSCLC all comers in 1st L. Outcome in all PDL1 strata mirroring CT+IO. Can we spare chemo in these pts regardless of PDL1 expression or just for high PDL1?Better outcomes with chemo-adagrasib-pembro but higher tox? IcORR? #ASCO25

More is really better for all?: Dato-Dxd+pembro+/-chemo in 1st L 🫁. TROP2 NMR is a predictive bmk to enrich population who may benefit the of adding this ADC but small sample size, and QoL of this intensive treatment? Do we need maintenance DatoDxd + Pembro? Too much…#ASCO25

AntiPd1 Benmelostat + anlotinin improved PFS vs pembro in 1st L 🫁 all PDL1. But Pembro alone is not the SoC in 1st L.Benefit mainly driven by high PDL1. Is benmel + anlotinib > ivonescimab (bispecific Pd1/VEGFR)?Data suggestIO+antiangiogenic is appropriate in 1st L hPDL1.#ASCO25

Sequential ttx with zipalertinib after amiv is feasible in pts with EGFRex20ins 🫁. Hwr,this agent is tested in 1stL in combo with CT. Best ttx: CT-Ami —> TKI vs TKI +\_CT —> Ami —> CT?. It’s not the strongest the first, it’s the all sequence treatment that impacts OS #ASCO25

More data supports KRASi + IO in 1L NSCLC with mKRAS G12C. Today: olomorasib+pembro with high ORR regardless PDL1. (Adagrasib+pembro ⬆️activity in PDL1>50%) Hwvr, how comut (STK11/KEAP1) impact the efficacy of these combos? Should we add Chemo when exist comut at baseline?#ASCO25